Director, HEOR Strategy - Oncology

About Abb Vie

Abb Vie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas including immunology, oncology and neuroscience - and products and services in our Allergan Aesthetics portfolio. For more information about Abb Vie, please visit us at  
Follow @abbvie on Linked In, Facebook, Instagram, X and You Tube.

The Oncology HEOR Strategy team, within the MHI Value & Evidence function, leads the creation and communication of transformative evidence to shape healthcare decision-making and make a remarkable impact for patients.

Director, HEOR Strategy, CLL & Heme-Oncology (HEOR‑S) – directs, develops, organizes, and implements the V&E strategy for Chronic Lymphocytic Leukemia (CLL) and disease adjacencies with concurrence of functional management to allow the development of each asset to proceed expeditiously and smoothly toward registration, PR&A and market launch in compliance with national and international governmental regulations for various asset programs, including CLL adjacencies.

HSL reports to Senior Director, Heme-Oncology HEOR Strategy Team Lead and may have direct reports.

• Accountable for engagement and co‑creation of holistic value evidence strategy with V&E pillars and cross‑functional partners for Oncology disease areas/assets/brands, including co‑creation of PCM deliverables, MHI Worldwide Scientific Plan, and Value & Evidence Plans (VEP) and ensuring timely relevance to disease area strategy, product development, competitive landscape, and the marketplace.
• Directs the design, conduct, and analysis of projects within each product area strategy across multiple programs, in partnership with V&E Centers of Excellence (PCOR, VAC, RWE, EPE, MPS) and is accountable for project execution, budget and meeting/exceeding ethical, scientific, regulatory, commercial, and quality requirements.
• HSL interacts/engages with cross‑functional leaders for CLL disease area. Effectively communicates findings to internal leadership (Executive Leadership, Area VPs, GMs etc.) and external (e.g. HTAs/Payers, patient advocacy groups and KOLs etc.)
• In the post‑marketing setting, this position is responsible for developing and executing V&E product life‑cycle and labeling strategies. Responsible for integrating the expressed needs for value demonstration from customers (physicians, patients, payers, policy‑makers), the direction of the commercial organization in product marketing and the realities of the science surrounding a product in developing strategies.
• Assumes full strategic V&E support of commercialization activities including the facilitation of obtaining and maintaining market access and growing/defending the market.
• Accountable for end‑to‑end delivery of V&E book of work under their remit, from strategy development to content pull through.
• Accountable for ensuring strong partnership with MHI, IMAP and all relevant V&E pillars to ensure a holistic and comprehensive voice to accelerate global patient access, in cross‑functional meetings.
• Partners with Heme‑Oncology HEOR Strategy Team Lead to shape CLL oncology patient access policy environment, including successfully engaging and collaborating HTA/ payers, clinical practice guideline organizations and US oncology pathway stakeholders.
• Partners with Heme‑Oncology HEOR Strategy Team Lead to establish external alliances to drive Heme‑Oncology payer/pathway centric fit‑for‑purpose evidence generation in support of pre‑ and post‑launch assets.
• Develops and maintains CLL oncology research partnerships with academic and community oncology centers and pathways to demonstrate the clinical, economic, humanistic and societal value of innovative Abb Vie therapies.

• Advanced degree required: MSc, MPH, or MBA with 10+ years of relevant experience; or PharmD/PhD with 7+ years in HEOR, market access, or a related research‑focused field.
• Deep expertise in HEOR methods including health economic modeling, patient‑reported outcomes,…